Introduction: A previous pilot study has demonstrated the feasibility of a novel
| INTRODUCTION
Quality assurance (QA) is an essential procedure to assess accuracy of relevant parameters in radiotherapy 1 while an external audit is recommended to assess consistency of local QA and effectiveness of delivery and measurement systems. 2 The importance of external audits is emphasized in radiotherapy clinical trials where a consistent accuracy is essential. [3] [4] [5] Conventional audits are performed by sitevisits or postal methods, which can be expensive and/or labor intensive. [6] [7] [8] Some virtual methods have been explored to reduce the audit cost using in-house QA methods. 9 Recently a novel approach was introduced to remotely assess intensity modulated radiotherapy (IMRT) deliveries using pre-treatment images from electronic portal imaging devices (EPIDs). The method was known as the Virtual Epid Standard Phantom Audit (VESPA) and designed for dosimetric auditing of clinical trials at remote facilities. The VESPA utilized an in-house software for analysis and provided a relatively consistent detection system for data acquisition. 10 Participating facilities were provided with CT data sets of the virtual water phantoms and transferred prostate and head and neck IMRT treatment plans onto these to calculate dose in their local treatment planning system (TPS). They electronically sent their images and planned dose to the auditing site for assessment.
The in-house software of the VESPA back-projects in-air acquired images from EPIDs into virtual water phantoms and converts the signals to dose at 10 cm depth within the phantoms.
11,12
The conversion is performed based on a model developed by King et al. at Calvary Mater Newcastle Hospital (CMNH). The software input includes a machine specific file, a beam model file and DICOM images and doses. The machine specific file refines the input and adapts it to each machine/delivery system using the facility calibration images. This file includes parameters defining central axis coordinate on the EPID and EPID-linac sag correction. Another software input is the beam model file referred to here as the Varian model (VM). The VM is not adjusted for each facility. It has been developed using aS1000 EPID acquired images from a Varian linac deliveries (vendor 1) of series of square fields. The beam profiles and field size factors (FSFs) of the deliveries were also measured in water tank and used for the VM optimization. The VM has been extensively benchmarked and used for vendor 1 in-house QA.
Six facilities took part in a pilot study of the remote based auditing method. Three of the facilities acquired data from Varian delivery and measurement systems (vendor 1) and three from Elekta (vendor 2). 13 The pilot study used the VM for both vendors but applied primary vendor differences to the machine speci- 14 Moreover, prior to analysis, acquired images at 160 cm source to detector distance (SDD) from vendor 2 were resampled to 100 cm. The ".HIS" format images acquired from iViewGT EPIDs were also converted to DICOM in consistent with the software input requirement. In spite of the applied differences to each machine file, slightly lower gamma pass rates were observed in the auditing results from vendor 2. The vendor 2 systems also demonstrated a different field size response for reconstructed dose at the phantom isocentre compared with those from vendor 1. These all could be due to the differences of relevant dosimetry characteristics between the two vendors. Ignoring the differences can result in significant uncertainties in the audit outcome. 15 Accordingly, this research studies relevant dosimetric variations between the two vendors and corresponding dose conversion models. Then, it investigates whether using vendor specific models could make the audit results independent from the vendors.
This research investigates differences of the beam profiles and FSFs, for the two vendors. The parameters are used in the development of the image to dose conversion model which in turn is applied for data analysis of the remote EPID based audit.
This study develops a model (EM) to convert images from EPID to dose inside the virtual phantom for vendor 2 deliveries. Then, the EM performance is compared with the VM for measured water tank data from vendor 2 deliveries. The EM is used for remote auditing of 54 IMRT fields from four vendor 2 facilities.
Statistical study of the auditing results determines whether a vendor specific model is required for auditing of each vendor.
This work will facilitate implementation of this new and efficient auditing procedure using a remote EPID based dosimetry with improved sensitivity. . All images were acquired at 160 cm SSD and resampled to 100 cm SSD using interpolation. The images were truncated at about 1 cm of the detector edge to avoid the edge artefacts. As the images were found noisier than those from aS1000 EPIDs, an adaptive "wiener2" filter in MATLAB was used to reduce the image noise and its impact on the model convolution function. The "wiener2" low pass filters the images that have been degraded by a constant power additive noise. It uses a pixel wise adaptive method based on statistics estimated from a local neighborhood of each pixel. 18 An initial trial EM could not consistently predict the FSFs for the four facilities. After investigation, an averaged FSF from the TPSs of the four facilities was used as the reference FSF for modeling purposes, see Supporting information.
| MATERIALS AND METHODS

2.A | Dosimetry
The EM model accuracy was quantified via calculating discrepancy between the image and water tank dose for the profiles and FSFs
where "nfield" was number of dose measurements/points. Furthermore, percentage differences were calculated for the EM dose 
2.C | Auditing
The EM was used to convert pre-treatment images from IMRT deliveries, a post-prostatectomy (PP) and a head and neck (HN) plan, to dose for four vendor 2 facilities. Details of these plans and the audit procedures are detailed elsewhere. 10, 13 Each facility delivered (7) (8) (9) IMRT fields per patient plan. For each field, the converted EPID dose was compared to corresponding TPS dose. The comparisons were performed by an in-house developed gamma function at three different criteria, 3%/3 mm, 3%/2 mm, and 2%/2 mm. The EM performance was compared with the VM performance for the IMRT audits at 1%/1 mm gamma criteria. Finally, a statistical study was conducted on the pilot audit including facilities from both vendors to compare performance of the vendor specific models and VM solely applied to all facilities. 3.C | Auditing The HN data from C 2 were not considered in any analysis as they had acquired calibration images at a different date from other EPID measurements. The audit result of each treatment site was assessed by pass rate boxplots and corresponding mean gammas. The HN mean gamma pass rates were (99.9 ± 0.2)%, (98.8 ± 1.7)% and (97.1 ± 3.6)% at respectively 3%/3 mm, 3%/2 mm and 2%/2 mm. The mean pass rates for the PP were (99.8 ± 0.7)%, (98.4 ± 2.7)%, and (96.9 ± 2.5)% at the criteria. Interquartile ranges of the pass rates the HN and almost all PP fields from all facilities showed improved gamma results (lower mean gammas) for the EM than VM. Figure 7 compares results of the pilot audit when using the VM for both vendors (blue boxplots) and when using vendor specific models (red boxplots) at 3%/3 mm criteria. Using analysis of variance (ANOVA) and Tukey-Kramer HSD methods for comparison of the mean gammas for the two scenarios, the former demonstrated a significant audit difference between two vendors (P < 0.0001). The mean gamma difference for the two vendors was reduced when using vendor specific models (P = 0.0025).
| RESULTS
3.A | Dosimetry
| DISCUSSION
The VESPA auditing procedure is designed as an inexpensive and efficient auditing procedure that can be performed remotely with the time for the central site physicist generally being 2-3 h to assess the results. The audit requires time from the local physicists to produce the IMRT verification plans and deliver the beams to the EPID, however, all other auditing methods require local personnel time.
The VESPA also does not include any equipment or transport costs.
The studies on the method has been conducted on two vendors using one vendor verified model (VM) to convert the image signal to dose inside the phantom. Investigation for the need for vendor specific models makes the audit reliable over different vendors.
Studies on relevant EPID measured dosimetric parameters showed differences between the two vendors. The discrepancy increased between the vendors' profiles at the very small/large field sizes, F I G . 7. Auditing results for a study including two vendors. It uses either the VM or vendor specific models for dose conversion. The VM shows a significant difference between the two vendors (P < 0.0001). Using vendor specific models demonstrates less significant difference between the vendors (P = 0.0025).
T A B L E 1 Mean gamma pass rates at 1%/1 mm for four vendor 2 facilities and two patient plans using both the EM and VM. over, showed relatively similar response to the EM for the PP. In general, using the EM for auditing vendor 2 facilities reduced mean gammas though, the differences between the EM and VM performances were not easily observed unless a highly strict gamma criteria, that is, 1%/1 mm, was used. This is in accordance with the above observations showing small improvement for calculating FSF dose.
The new EM and the VM were used to convert dose for deliveries from respectively vendor 2 and vendor 1 facilities in a study. The deliveries were also analysed using only VM for both vendors. Statistical studies of the two scenarios demonstrated a minor improvement when using vendor specific models (P = 0.0025) than the VM (P < 0.0001). Vendor dependency of the auditing results reduced when using vendor specific models (EM for vendor 2 and VM for vendor 1). However, mean gammas for vendor 2 were still larger than for vendor 1. This could be due to the impact of other variables such as facility TPS types which were not considered in this study.
| CONCLUSION
Observed differences in relevant dosimetry parameters between vendor 1 and vendor 2 suggested using vendor specific models, to convert signal to dose onto the virtual phantoms, could account for dosimetry differences between the vendors. By developing a new model (EM) and using vendor specific models, the EM for vendor 2 and VM for vendor 1, the audit difference reduced between two vendors. The audit accuracy was improved and using vendor specific models was advised for future audits. The remote audit approach provides a highly automated method with significantly reduced cost.
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